Lexaria Bioscience
LEXX
29 hedge funds and large institutions have $920K invested in Lexaria Bioscience in 2026 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
71% more capital inflows, than outflows
Capital inflows: $259K | Capital outflows: $151K
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
16% more funds holding
Funds holding: 25 → 29 (+4)
0.63% more ownership
Funds ownership: 5.99% → 6.62% (+0.63%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$104K |
| 2 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$55K |
| 3 |
HRT Financial
New York
|
+$33.7K |
| 4 |
StoneX Group
New York
|
+$18.6K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$15.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invenomic Capital Management
Boston,
Massachusetts
|
-$69.8K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$31.6K |
| 3 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$28.9K |
| 4 |
BCV Asset Management
Winnipeg,
|
-$7.8K |
| 5 |
Vontobel Holding
Zurich,
Switzerland
|
-$5.64K |
LEXX Hedge Fund Activity: Q2 2026 in Review
29 of the 8,376 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q2 2026, worth a combined $920K — down 21% from $1.17M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new LEXX positions and 3 closed out — a net gain of 4 holders — while 8 added to existing stakes and 6 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $104K. The largest seller was Invenomic Capital Management, cutting an estimated $69.8K.
- 29 institutional investors held Lexaria Bioscience (LEXX) as of Q2 2026, up from 25 in Q1 2026.
- Funds reported $920K of Lexaria Bioscience stock for Q2 2026, down 21% quarter-over-quarter.
- 7 funds opened new Lexaria Bioscience positions in Q2 2026 and 3 closed out, a net change of +4 holders.
- The largest Lexaria Bioscience buyer in Q2 2026 was Citadel Advisors, an estimated $104K added.
- The largest Lexaria Bioscience seller in Q2 2026 was Invenomic Capital Management, an estimated $69.8K sold.
Based on aggregated 13F filings for Q2 2026.